DepoMed to buy U.S. rights to Nucynta from J&J unit

DepoMed agrees to buy the U.S. license rights to the painkiller Nucynta from Janssen Pharmaceuticals, a unit of Johnson & Johnson, for $1.05 billion.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.